Loredana Crista Tiuca

Dr. Loredana Crista Tiuca


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Antibiotics
Verified
Journal Article
Open access
NANinel Iacobus Antonie
Ninel Iacobus Antonie
GGGina Gheorghe
Gina Gheorghe
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
LTLoredana Crista Tiuca
Loredana Crista Tiuca
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Background/Objectives: Antimicrobial resistance represents a growing global health crisis, demanding innovative approaches to improve antibiotic stewardship. Artificial intelligence (AI) chatbots based on large language models have shown potential as tools to support clinicians, especially non-specialists, in optimizing antibiotic therapy. This review aims to synthesize current evidence on the capabilities, limitations, and future directions for AI chatbots in enhancing antibiotic selection and patient outcomes. Methods: A narrative review was conducted by analyzing studies published in the last five years across databases such as PubMed, SCOPUS, Web of Science, and Google Scholar. The review focused on research discussing AI-based chatbots, antibiotic stewardship, and clinical decision support systems. Studies were evaluated for methodological soundness and significance, and the findings were synthesized narratively. Results: Current evidence highlights the ability of AI chatbots to assist in guideline-based antibiotic recommendations, improve medical education, and enhance clinical decision-making. Promising results include satisfactory accuracy in preliminary diagnostic and prescriptive tasks. However, challenges such as inconsistent handling of clinical nuances, susceptibility to unsafe advice, algorithmic biases, data privacy concerns, and limited clinical validation underscore the importance of human oversight and refinement. Conclusions: AI chatbots have the potential to complement antibiotic stewardship efforts by promoting appropriate antibiotic use and improving patient outcomes. Realizing this potential will require rigorous clinical trials, interdisciplinary collaboration, regulatory clarity, and tailored algorithmic improvements to ensure their safe and effective integration into clinical practice.

24 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
GGGina Gheorghe
Gina Gheorghe
IBIoana Alexandra Baban
Ioana Alexandra Baban
ABAlexandru Barbu
Alexandru Barbu
TGTeodor Florin Georgescu
Teodor Florin Georgescu
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Background and Objectives: Early-onset colorectal cancer (EO-CRC) has become a significant public health concern due to its alarming rise in incidence and the poor prognosis associated with this disease. The aim of our study was to identify epidemiological, clinical, and paraclinical characteristics that could explain the more aggressive evolution of EO-CRC compared to late-onset colorectal cancer (LO-CRC). Materials and Methods: We conducted a retrospective study over a two-year period, including 204 patients diagnosed with colorectal cancer (CRC). The patients were divided into two subgroups: those with EO-CRC and those with LO-CRC. Statistical analysis was performed using IBM SPSS Statistics, Version 29.0. Results: EO-CRC was identified in 11.3% of the patients included in the study. Compared to LO-CRC patients, EO-CRC patients exhibited a tendency for more distal tumor localization and a stenotic endoscopic appearance (43.5% vs. 29.3%). Regarding histopathological diagnosis, EO-CRC patients demonstrated a higher proportion of the mucinous histologic subtype (34.8% vs. 14.4%) and a significantly greater percentage of poorly differentiated tumors (39.1% vs. 14.5%; p = 0.010). Immunohistochemical results, available for a limited number of patients, revealed higher CDX2 positivity in LO-CRC patients (p = 0.012) and higher HER2 positivity in EO-CRC patients (p = 0.002). Smoking (p = 0.006) and hypertension (p = 0.002) were more prevalent in EO-CRC patients than in LO-CRC patients. Conclusions: Patients with EO-CRC exhibit distinct histopathological and molecular characteristics compared to those with LO-CRC, which may contribute to their poorer prognoses. The higher prevalence of the mucinous histological subtype, poor tumor differentiation, increased HER2 expression, and reduced CDX2 expression suggest potential molecular pathways driving the aggressive nature of EO-CRC. These findings highlight the need for tailored screening strategies and personalized therapeutic approaches in younger CRC patients. Future studies should further investigate the underlying mechanisms and potential biomarkers that could guide early diagnoses and targeted treatments.

16 January 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
GGGina Gheorghe
Gina Gheorghe
TGTeodor Florin Georgescu
Teodor Florin Georgescu
VBVlad Buica
Vlad Buica
MCMihai-Stefan Catanescu
Mihai-Stefan Catanescu
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Despite many advances in the management of patients with colorectal cancer, this malignancy remains the second leading cause of cancer death worldwide. One of the keys to improve the prognosis of these patients is diagnosis in early stages, making them eligible for curative surgical treatment. Cutaneous paraneoplastic syndromes can enhance the diagnostic management of these patients. The time elapsed from the appearance of skin lesions to the appearance of the first digestive symptoms can reach up to a decade. Thus, comprehensive paraclinical evaluation and the monitoring of patients with specific skin lesions play an important role in detecting an underlying cancer. Given these findings, it is imperative to increase the awareness of cutaneous paraneoplastic syndromes among patients and medical professionals. Additionally, the investigation of the mechanisms that elucidate this pathogenic link has the potential to result in the identification of novel therapeutic targets.

8 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
LTLoredana Crista Tiuca
Loredana Crista Tiuca
GGGina Gheorghe
Gina Gheorghe
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
NANinel Iacobus Antonie
Ninel Iacobus Antonie
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Background and Objectives: Chronic obstructive pulmonary disease (COPD) is a systemic condition in which muscle wasting, malnutrition, and altered fluid balance strongly influence prognosis. While spirometry remains essential for diagnosis and staging, it often fails to reflect the heterogeneity of outcomes. Multifrequency bioelectrical impedance analysis (MF-BIA) enables the assessment of body composition and fluid distribution, offering additional prognostic information. This systematic review aimed to evaluate the prognostic significance of MF-BIA in COPD, with emphasis on outcomes such as mortality, exacerbations, and hospital admissions. Materials and Methods: We systematically searched PubMed, Web of Science and Scopus from inception to 29 April 2025. The earliest record retrieved was published in 1996 but was excluded during screening. Studies including COPD patients in whom MF-BIA-derived parameters were related to clinical outcomes were eligible. Risk of bias was assessed using the Newcastle–Ottawa Scale. Data on design, population, methodology, and endpoints were extracted and narratively synthesized due to heterogeneity. The review protocol was not registered. Results: Eight studies were included. Phase angle (PhA) consistently showed prognostic value, being inversely related to mortality and rehospitalizations. Fat-free mass index (FFMI) was integrated into multidimensional models, but its independent role was inconsistent. Parameters describing fluid distribution, such as Extracellular Water/Total Body Water ratio, also appeared relevant, though interpretation was often limited by the absence of consistent consideration of underlying cardiac disease. Conclusions: MF-BIA provides useful prognostic insights in COPD patients, particularly through PhA. It may refine risk stratification beyond spirometry, yet further prospective studies with standardized methods are needed to confirm its independent value. Heterogeneity of methods and small sample sizes remain important limitations.

2 April 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
NANinel Iacobus Antonie
Ninel Iacobus Antonie
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
GGGina Gheorghe
Gina Gheorghe
LTLoredana Crista Tiuca
Loredana Crista Tiuca
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Background/Objectives: Antimicrobial resistance (AMR) remains a major global health threat, strengthening the case for antimicrobial stewardship strategies that limit unnecessary broad-spectrum empiric therapy while preserving timely escalation when clinically warranted. Before any clinical deployment of large language model (LLM)-based antibiotic decision support can be considered, structured offline evaluation is needed to assess whether model outputs align with auditable stewardship constraints under real-world admission contexts. We therefore evaluated whether post hoc LLM-generated empiric antibiotic recommendations showed greater concordance with a pre-specified stewardship benchmarking framework than clinician-initiated regimens in a retrospective shadow-mode setting. Methods: Single-center retrospective paired evaluation at Clinical Emergency Hospital of Bucharest (Internal Medicine, 2020–2024). The unit of analysis was the admission (N = 493), with paired 24 h empiric regimens (clinician-prescribed vs. post hoc LLM-recommended via OpenAI API; not visible to clinicians; no influence on care). Local laboratory-derived epidemiology was precomputed from microbiology exports and provided as structured prompt context to approximate information parity with clinicians’ implicit local ecology knowledge. Primary (prespecified) endpoint: any contextual guardrail violation (unjustified carbapenem/antipseudomonal/anti-MRSA under prespecified structured severity/MDR-risk rules), exact McNemar. Key secondary (prespecified): Δ contextual guardrail penalty (LLM − Clin), sign test and Wilcoxon signed-rank (ties reported). Ethics committee approval was obtained. Results: Guardrail violations occurred in 17.0% of clinician regimens vs. 4.9% of LLM regimens (paired RD −12.2%; matched OR 0.216, 95% CI 0.127–0.367; McNemar exact p = 1.60 × 10−10). Δ penalty had median 0 with 398/493 ties; among non-ties, improvements (Δ < 0) exceeded adverse shifts (79 vs. 16; sign-test p = 3.47 × 10−11). Conclusions: In this offline, non-interventional paired evaluation, LLM-generated empiric regimens showed greater concordance with a pre-specified stewardship benchmarking framework than clinician empiric regimens for the same admissions. These findings should not be interpreted as evidence of clinical superiority, patient safety, or causal effectiveness, but rather as process-level benchmarking within a rule-based stewardship construct. As such, reproducible guardrail-based benchmarking may serve as an early pre-implementation step to identify alignment and potential failure modes before prospective, safety-governed evaluation.

17 December 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
VIVlad Alexandru Ionescu
Vlad Alexandru Ionescu
ACAlice Elena Ciontu
Alice Elena Ciontu
GIGabriel Ianuș
Gabriel Ianuș
VBVlad Buica
Vlad Buica
Ancuța Iuliana NăstacAncuța Iuliana Năstac
Ancuța Iuliana Năstac
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
Celiac disease (CeD) is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals, with a heterogeneous clinical spectrum spanning classical gastrointestinal symptoms, extraintestinal manifestations, and subclinical forms. We synthesize contemporary epidemiology, immunopathogenesis, and the updated 2025 European Society for the Study of Coeliac Disease diagnostic framework. Adaptive responses to deamidated gliadin peptides presented by human leukocyte antigen (HLA)-DQ2/DQ8, together with interleukin-15-driven activation of intraepithelial lymphocytes (IELs), culminate in villous atrophy, crypt hyperplasia, and increased IELs. Serology centered on tissue transglutaminase immunoglobulin A (tTG-IgA) with total immunoglobulin A assessment remains first-line, complemented by standardized duodenal sampling (≥4 distal + 2 bulb biopsies) and selective HLA typing. The guidelines conditionally endorse a no-biopsy pathway for adults <45 years with tTG-IgA ≥10× upper limit of normal confirmed on a second sample, emphasizing shared decision-making and exclusion of red flags. We delineate differential diagnoses (tropical sprue, Crohn’s disease, common variable immunodeficiency, small intestinal bacterial overgrowth) and contrast CeD with non-celiac gluten sensitivity, which lacks villous atrophy, disease-specific serology, and HLA association. Emerging tools (immunohistochemistry, CD3/CD8/γδ IELs, video capsule endoscopy, confocal laser endomicroscopy) and the limitations of salivary/fecal assays are reviewed. Early detection improves quality of life and reduces healthcare utilization. Future directions include artificial intelligence-assisted imaging, molecular immunophenotyping, and non-dietary therapeutics.